Latest Breaking News On - Julie mcelrath - Page 2 : comparemela.com

Overactive Inflammatory Response Responsible for Many Cases of Long COVID

Overactive Inflammatory Response Responsible for Many Cases of Long COVID
insideprecisionmedicine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideprecisionmedicine.com Daily Mail and Mail on Sunday newspapers.

Fred hutchAarthi tallaTroy torgersonJulie mcelrathJulie czartoskiInfectious disease divisionAllen institute for immunologyAllen instituteNature communicationsFred hutchinson cancer centerExperimental immunologyJanus kinase

Study:Overactive inflammatory response could be at the root of many long COVID cases

An overactive inflammatory response could be at the root of many long COVID cases, according to a new study from the Allen Institute and Fred Hutchinson Cancer Center.

Troy torgersonJulie mcelrathDanielle ellisFred hutchSuhas vasaikarTom bumolAarthi tallaJulie czartoskiAllen instituteInfectious disease divisionAllen institute for immunologyFred hutchinson cancer centerResearch clinicianNature communicationsFred hutchinson cancerSenior vice president

Many long COVID patients suffer from persiste

Many long COVID patients suffer from persiste
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Troy torgersonTom bumolAarthi tallaJulie czartoskiSuhas vasaikarFred hutchJulie mcelrathPaulg allenFred hutchinson cancer centerMethod of researchAllen instituteAllen institute for cell scienceMindscope programNature communicationsResearch clinicianInfectious disease division

Nanoparticle HIV vaccine shows potential in trial

Positive first-in-human trial results have highlighted potential of a nanoparticle vaccine towards broadly neutralising against HIV.

Julie mcelrathAntibody centerNational institute of allergyDepartment of immunologyInfectious disease divisionMelinda gates foundation collaborationAntibody center at scripps researchRagon instituteScripps researchScience translational medicineSenior vice presidentFred hutchInfectious diseaseWilliam schiefExecutive directorNational institute

First-in-human nanoparticle HIV vaccine induces broad and publicly targeted helper T cell responses

Researchers from Fred Hutchinson Cancer Center in Seattle, Scripps Research in La Jolla, California, IAVI and other collaborating institutions have characterized robust T-cell responses in volunteers participating in the IAVI G001 Phase 1 clinical trial to test the safety and immune response of a self-assembling nanoparticle HIV vaccine.

United statesJulie mcelrathFred hutchLily ramseyAntibody center at scripps researchAntibody centerDepartment of immunologyRagon instituteScripps research in la jollaMelinda gates foundation collaborationNational institute of allergyScripps researchInfectious disease divisionFred hutchinson cancer centerScience translational medicineVaccine trials unit